DVA

From a fundamental perspective, DaVita shows robust performance metrics. The company has reported an impressive earnings per share (EPS) of $10.37, with a quarter-over-quarter growth rate of 43.5%. Revenue growth is equally notable, with a 6.0% increase QoQ and an extraordinary 645.7% growth year-over-year. The gross margin of 2700.5% and operating margin of 1473.7% highlight exceptional profitability. With a market capitalization of $13.34 billion, the stock is currently trading at a price-to-earnings (P/E) ratio of 20.1 and a forward P/E of 14.3, suggesting that the stock is fairly valued relative to its growth trajectory. Analyst consensus remains neutral with a HOLD rating, comprising 0 strong buys, 2 buys, 4 holds, and 0 sells, with a target price averaging $193.71, indicating limited upside from current levels.

Earnings are not scheduled within the next 30 days, which may limit immediate catalysts for the stock. Notably, the last quarter's performance, reported on March 31, 2026, will be critical to watch for any signs of margin compression or revenue deceleration that could affect investor sentiment. Recent news highlighting efforts to strengthen the transplant system and the focus on DaVita's long-term dialysis model may provide strategic insights, but the lack of imminent earnings may keep the stock in a holding pattern. Investors should monitor for any developments in operational efficiencies or strategic initiatives that could influence future earnings and stock performance.